News Conference News ESC 2025 DAPT’s Role After CABG Questioned: TACSI and TOP-CABG Caitlin E. Cox September 05, 2025
News Conference News ESC 2022 Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke Todd Neale August 28, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Conference News ESC 2021 OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT Shelley Wood September 02, 2021
News Conference News ESC 2020 New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials Caitlin E. Cox September 03, 2020
News Conference News ESC 2019 For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI Todd Neale September 03, 2019
News Conference News ESC 2019 AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD Todd Neale September 02, 2019
News Conference News ESC 2018 New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All Michael O'Riordan August 29, 2018
News Conference News ESC 2017 COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease Todd Neale August 27, 2017
News Conference News ESC 2015 NSAIDs Plus Anticoagulants a Bad Combination Caitlin E. Cox September 01, 2015
News Conference News ESC 2013 New Alternatives Match Efficacy to Warfarin in High-Risk Subgroups Caitlin E. Cox September 03, 2013
News Conference News ESC 2013 Novel Anticoagulant Edoxaban Surpasses Warfarin Across Spectrum of VTE Patients Caitlin E. Cox September 02, 2013
News Conference News RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets August 31, 2011